At the 2023 ASCO Gastrointestinal Cancers Symposium, Wainberg et al presented results from NAPOLI-3, a randomized, open-label, phase III study investigating the efficacy and safety of NALIRIFOX compared with nab-paclitaxel plus gemcitabine as first-line therapy in patients with metastatic pancreatic cancer (Abstract LBA661).
